Current approaches and challenges in managing and monitoring treatment response in ovarian cancer

Journal of Cancer

Volumn 5, Issue 1, 2014, Pages 25-30

  Marcus, Charlotte S ^a,b   Maxwell, G Larry ^a,c   Darcy, Kathleen M ^a   Hamilton, Chad A ^a,b   McGuire, William P ^c  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Ovarian Cancer; Treatment Response

Indexed keywords

CA 125 ANTIGEN;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CAUSE OF DEATH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HEALTH CARE COST; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PERSONALIZED MEDICINE; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT RESPONSE;

EID: 84893586947     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7810     Document Type: Review

References (49)

1. [Internet] Howlader N NA, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2010. http://seercancergov/csr/1975_2010/
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63: 11-30.
3. Salani R, Backes FJ, Fung Kee Fung M, Holschneider CH, Parker LP, Bristow RE, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. American Journal of Obstetrics and Gynecology. 2011; 204: 466-78.
4. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer. New England Journal of Medicine. 1996; 334: 1-6.
5. von Georgi R, Schubert K, Grant P, Munstedt K. Post-therapy surveillance and after-care in ovarian cancer. European journal of obstetrics, gynecology, and reproductive biology. 2004; 114: 228-33.
6. Geurts SM, de Vegt F, van Altena AM, Tjan-Heijnen VC, Massuger LF, Adang EM, et al. Impact of routine follow-up examinations on life expectancy in ovarian cancer patients: a simulation study. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2012; 22: 1150-7.
7. Kew F, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane database of systematic reviews (Online). 2011;: Cd006119.
8. Miller RE, Rustin GJ. How to follow-up patients with epithelial ovarian cancer. Current opinion in oncology. 2010; 22: 498-502.
9. Armstrong DK. Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease. The Oncologist. 2002; 7: 20-8.
10. Rettenmaier NB, Rettenmaier CR, Wojciechowski T, Abaid LN, Brown JV III, Micha JP, et al. The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. Br J Cancer. 2010; 103: 1657-62.
11. Chan KKL, Tam KF, Tse KY, Ngan HYS. The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecologic Oncology. 2008; 110: 158-61.
12. Fehm T, Heller F, Kramer S, Jager W, Gebauer G. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer research. 2005; 25: 1551-4.
13. Menczer J, Chetrit A, Sadetzki S, Golan A, Levy T. Follow-up of ovarian and primary peritoneal carcinoma: The value of physical examination in patients with pretreatment elevated CA125 levels. Gynecologic Oncology. 2006; 103: 137-40.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute. 2000; 92: 205-16.
15. Eisenhauer EA. Optimal assessment of response in ovarian cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011; 22 Suppl 8: viii49-viii51.
16. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2011; 21: 419-23.
17. Markman M. The Myth of Measurable Disease in Ovarian Cancer. Journal of Clinical Oncology. 2003; 21: 3013-5.
18. Hopper KD, Kasales CJ, Van Slyke MA, Schwartz TA, TenHave TR, Jozefiak JA. Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR American journal of roentgenology. 1996; 167: 851-4.
19. Gwythen S, Bolis G, Gore M, Huinink WtB, Verweij J, Hudson IR, et al. Experience with independent radiological review during a topotecan trial in ovarian cancer. Annals of Oncology. 1997; 8: 463-8.
20. Muenzel D, Engels HP, Bruegel M, Kehl V, Rummeny EJ, Metz S. Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1. Radiology and oncology. 2012; 46: 8-18.
21. Grolund B HC, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumores (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol. 2004; 22: 4051-8.
22. Pignata S, Cannella L, Leopardo D, Bruni GS, Facchini G, Pisano C. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011; 22 Suppl 8: viii40-viii4.
23. Rustin GJS. Can We Now Agree to Use the Same Definition to Measure Response According to CA-125? Journal of Clinical Oncology. 2004; 22: 4035-6.
24. Testa AC, Fruscella E, Ludovisi M, De Vincenzo R, Malaggese M, Corrado G, et al. The role of sonographic examination in the follow-up of gynecological neoplasms. Gynecol Oncol. 2005; 99: 696-703.
25. Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Critical reviews in oncology/hematology. 2009; 71: 43-52.
26. Stacey A. Funt HH, Nadeem Abu-Rustum, Madhu Mazumdar, Howard Felderman and Dennis S. Chi. Role of CT in the Management of Recurrent Ovarian Cancer. American Journal of Roentgenology. 2004; 182: 393-8.
27. Bharwani N, Reznek RH, Rockall AG. Ovarian Cancer Management: the role of imaging and diagnostic challenges. European journal of radiology. 2011; 78: 41-51.
28. Javitt MC. ACR Appropriateness Criteria on staging and follow-up of ovarian cancer. Journal of the American College of Radiology: JACR. 2007; 4: 586-9.
29. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007; 105: 17-22.
30. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2010; 21: v23-v30.
31. Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2010; 20: 936-44.
32. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003; 90: 519-28.
33. Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer. Clinica chimica acta, international journal of clinical chemistry. 2013; 415: 341-5.
34. Song MJ, Lee SH, Choi MR, Son HJ, Lee CW, Yoon JH, et al. Diagnostic value of CA125 as a predictor of recurrence in advanced ovarian cancer. European journal of gynaecological oncology. 2013; 34: 148-51.
35. Gadducci A, Sartori E, Zola P, Landoni F, Maggino T, Palai N, et al. Serum CA125 assay in the early diagnosis of recurrent epithelial ovarian cancer. Oncology reports. 1996; 3: 301-3.
36. Bast RC, Jr., Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. The International journal of biological markers. 1998; 13: 179-87.
37. Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2012; 124: 563-8.
38. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010; 376: 1155-63.
39. Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010; 117: 336-40.
40. Al Rawahi T LA, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane database of systematic reviews (Online). 2013.
41. Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. The Role of Secondary Surgery in Recurrent Ovarian Cancer. International Journal of Surgical Oncology. 2012; 2012: 6.
42. Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Annals of Oncology. 2005; 16: 47-50.
43. Liu PY, Alberts DS, Monk BJ, Brady M, Moon J, Markman M. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25: 3615-20.
44. Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Annals of Oncology. 2008; 19: 327-31.
45. Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006; 24: 1454-8.
46. Bertholf RL, Johannsen L, Guy B. False elevation of serum CA-125 level caused by human anti-mouse antibodies. Annals of clinical and laboratory science. 2002; 32: 414-8.
47. Oei ALM, Sweep FCGJ, Massuger LFAG, Olthaar AJ, Thomas CMG. Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody. Gynecologic Oncology. 2008; 109: 199-202.
48. Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer. 2008; 112: 1726-32.
49. Bradley EJ, Pitts MK, Redman CW, Calvert E. The experience of long-term hospital follow-up for women who have suffered early stage gynecological cancer: a qualitative interview study. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 1999; 9: 491-6.